Autoimmune Memory T Helper 17 Cell Function and Expansion Are Dependent on Interleukin-23  by Haines, Christopher J. et al.
Cell Reports
ReportAutoimmune Memory T Helper 17 Cell Function
and Expansion Are Dependent on Interleukin-23
Christopher J. Haines,1 Yi Chen,1 Wendy M. Blumenschein,1 Renu Jain,1 Charlie Chang,1 Barbara Joyce-Shaikh,1
Katherine Porth,1 Katia Boniface,1,3 Jeanine Mattson,1 Beth Basham,1 Stephen M. Anderton,2 Terrill K. McClanahan,1
Svetlana Sadekova,1 Daniel J. Cua,1 and Mandy J. McGeachy1,4,*
1Merck Research Laboratories, 901 California Avenue, Palo Alto, CA 94304, USA
2MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent,
Edinburgh EH16 4TJ, UK
3Present address: Laboratoire INSERM U1035, Universite´ Bordeaux Segalen, 33076 Bordeaux, France
4Present address: Department of Medicine, Division of Rheumatology andClinical Immunology, University of Pittsburgh, 3500 Terrace Street,
Pittsburgh, PA 15261, USA
*Correspondence: mmcgeach@pitt.edu
http://dx.doi.org/10.1016/j.celrep.2013.03.035SUMMARY
Interleukin-23 (IL-23) is essential for the differentia-
tion of pathogenic effector T helper 17 (Th17) cells,
but its role in memory Th17 cell responses is unclear.
Using the experimental autoimmune encephalomy-
elitis (EAE) model, we report that memory Th17 cells
rapidly expanded in response to rechallenge and
migrated to the CNS in high numbers, resulting in
earlier onset and increased severity of clinical dis-
ease. Memory Th17 cells were generated from
IL-17+ and RORgt+ precursors, and the stability of
the Th17 cell phenotype depended on the amount
of time allowed for the primary response. IL-23 was
required for this enhanced recall response. IL-23
receptor blockade did not directly impact IL-17 pro-
duction, but did impair the subsequent proliferation
and generation of effectors coexpressing the Th1
cell-specific transcription factor T-bet. In addition,
many genes required for cell-cycle progression
were downregulated in Th17 cells that lacked IL-23
signaling, showing that a major mechanism for
IL-23 in primary and memory Th17 cell responses
operates via regulation of proliferation-associated
pathways.INTRODUCTION
The generation of memory T cells is an extremely useful event for
providing protective immunity to infectious agents. Autoimmu-
nity, on the other hand, represents a situation in which the gen-
eration of memory cells contributes to ongoing or recurring
disease. T helper 17 (Th17) cells are now strongly associated
with many human autoimmune and chronic inflammatory disor-
ders, including psoriasis, Crohn’s disease, rheumatoid arthritis,
multiple sclerosis, and uveitis (Korn et al., 2009; McGeachy
and Cua, 2008). In mouse models of these diseases, Th17 cells1378 Cell Reports 3, 1378–1388, May 30, 2013 ª2013 The Authorshave been shown to play a causative role. Many advances
have beenmade in our understanding of how Th17 cell activation
is regulated (reviewed extensively elsewhere; Boniface et al.,
2008; Korn et al., 2009).
Th17 cell recall responses have been shown to be effective in
vaccination models of Mycobacterium tuberculosis (Khader
et al., 2007), Coccidioides posadasii, Histoplasma capsulatum,
Blastomyces dermatitidis (Wu¨thrich et al., 2011), and Klebsiella
pneumoniae (Chen et al., 2011), as well as following infection
with Bordetella pertussis (Warfel and Merkel, 2012), Group A
Streptococcus (Dileepan et al., 2011), and Candida albicans
(Herna´ndez-Santos et al., 2012). Th17 cells appear to be inher-
ently plastic and easily convert to Th1, particularly in models of
autoimmunity (Bending et al., 2009; Hirota et al., 2011; Lee
et al., 2009; Martin-Orozco et al., 2009), which would suggest
that the subsequent memory response would be dominated by
Th1 cells. However, the characteristics of autoimmune memory
Th17 cell responses and requirements for interleukin 23 (IL-23)
have so far not been addressed.
Previous work from our laboratory showed that the IL-23
receptor (IL-23R) is required in vivo for effector Th17 cell re-
sponses (McGeachy et al., 2009). The requirement for IL-23
in the primary Th17 cell response might suggest that memory
responses would be impaired if IL-23 was absent at this stage.
In the absence of IL-23R, activated Th17 cells retain low IL-7Ra
expression (McGeachy et al., 2009), a receptor that is known to
be important for the survival of memory cells in CD8 popula-
tions (Kaech et al., 2003) and is also required for susceptibility
to the experimental autoimmune encephalomyelitis (EAE)
model (Walline et al., 2011). On the other hand, it was recently
shown that IL-7Ra does not delineate precursors that form
CD4+ T cell memory (Marshall et al., 2011). It remains contro-
versial whether memory cells emerge from effector cell popula-
tions or less differentiated cells; a weak effector response could
therefore predict either a poor or an enhanced memory
response. Finally, IL-23R blockade 1 week after immunization
is not effective in blocking the subsequent Th17 effector cell
response in EAE, suggesting that memory Th17 cells may
also not require IL-23 for their subsequent reactivation in vivo.
Therefore, we set out to investigate the requirements for IL-23
in autoimmune Th17 cell memory responses using an adapted
model of EAE.
RESULTS AND DISCUSSION
Autoimmune CD4+ Memory Cells Transfer Severe EAE
In order to examine the phenotype and function of autoimmune
memory CD4+ T cells, we developed a system in which memory
cells can be reactivated and analyzed separately from primary
effector cells in vivo. CD45.2+ mice were immunized with
MOG(35-55) in complete Freund’s adjuvant (CFA) to generate
MOG-specific Th17 cells, andCD4+ cells containing thismemory
population were then transferred into naive congenic recipients.
After an additional 2–9 weeks, the recipients were immunized
with MOG(35-55) to induce EAE. Cell-transfer recipients consis-
tently showed a faster onset and increased severity of clinical
scores compared with untransferred controls (Figures 1A, 1B,
and S1), correlating with a memory response. Unimmunized
recipients did not develop EAE, showing that the response is
dependent on secondary activation of the memory cells.
Analysis of CD45.2+ cells revealed a large expansion by day 4
postimmunization, reaching a peak in the lymph nodes (LNs) at
day 7 (Figure 1C), with a large increase in CD44hiCD27lo effectors
(Figure 1D) that produce IL-17 (Figure 1E). The proportion of
interferon-g+ (IFNg+) cells also increased over time, as has
been reported to occur in the primary Th17 cell response (Hirota
et al., 2011). Hence, it appeared that memory for Th17 cells was
stable in this system, in the sense that most of the cells initially
produced IL-17 and IFNg emerged later.
The initial expansion in the LNs was followed by a large efflux
of cells into the blood (Figure 1F) and infiltration into the CNS
(Figure 1G). A comparison of transferred memory cells with
endogenous primary activated cells in the CNS revealed that
the memory cells were not only present at slightly higher fre-
quencies but also produced more cytokine, particularly IL-17
(Figures 1G and 1H). These results show that memory Th17 cells
can be generated and tracked in our system, and these cells
strongly contribute to disease after re-exposure to antigen.
Memory Cells Are Generated from IL-17+ and RORgt+
Precursors
Whether memory CD4+ T cells are generated from effectors or
noncommitted Th0 cell precursors remains controversial, but
for Th1 cells, Yeh et al. (2011) demonstrated that memory cells
are generated from IFNg+ precursors. Also, Th17 cells have
been proposed to be inherently plastic, readily converting to
Th1. Therefore, we asked whether the IL-17+ memory cells we
observed were derived from the original IL-17-producing cells
present in the primary response by using IL-17-GFP reporter
mice as donors and sorting GFP+ cells on day 8 postimmuniza-
tion (Figure S2).
Recipients of IL-17-GFP+ cells consistently showed a faster
onset and increased severity of clinical scores compared with
recipients of IL-17-GFP cells (Figure 2A), and IL-17-GFP+ cells
were present in high numbers in the CNS, whereas few IL-17-
GFP transfer cells were present at that site (Figure 2B). By
day 11 of the secondary response, we found that most of the
originally IL-17-GFP+ cells were no longer producing IL-17 inCthe CNS and were instead positive for IFNg (Figure 2C). We
hypothesized that early removal of primed Th17 cells from the
inflammatory environment might have impaired their ability to
form stable Th17 memory. To address this, we waited until
day 18 after primary immunization to sort and transfer the
IL-17-GFP+ cells. In comparison with the day 8 transfers, day
18 cells showed a greater stability of the Th17 phenotype,
although there was still some conversion to IL-17+IFNg+ and
IFNg+ cells (Figures 2D and 2E). Therefore, it appears that
Th17 cells become more stable over time during the primary
response, and thismay be one factor contributing to the reported
plasticity of this population.
To investigate the expression of RORgt, we immunized
RORgt-GFP reporter mice as donors. Similarly to IL-17-GFP
sorted cells, the RORgt-GFP sorted cells initially produced
IL-17 with little IFNg (Figure 2F), followed by a small increase in
IFNg-producing cells. The cells that had maintained RORgt in
the secondary response were also the main producers of
IL-17, with a small proportion of double producers, whereas cells
that had downregulated RORgt produced some IFNg but little
IL-17 (Figure 2G). Corresponding with the increase in IFNg,
many of the previously RORgt+ cells expressed T-bet on
day 13 (Figure 2H). However, many RORgt+IL-17+ cells were
also T-bet+ (Figure 2I), suggesting that RORgt and T-bet expres-
sion are not necessarily mutually exclusive in Th17 cells.
Although these data confirm the inherently plastic nature of
Th17 cells, they also suggest that the memory population is
either generated before the conversion of effectors toward a
Th1 phenotype or that Th17 memory cells survive more readily
than ‘‘ex-Th17’’ Th1 cells, since the memory response is charac-
terized by the appearance of IL-17 producers before IFNg
producers.
IL-23 Is Required for Activation of the Recall Th17
Memory Response
In order to test whether memory Th17 cells required IL-23 for
their activation, we transferred CD4+ T cells from immunized
donors as before and administered anti-IL-23R to the recipients
at the time of challenge. Anti-IL-23R protected memory transfer
recipients from EAE induction with either CFA or incomplete
Freund’s adjuvant (IFA; Figures 3A, 3B, and S3). The percent-
age and number of memory cells in the LNs were reduced by
anti-IL-23R (Figure 3C), which was particularly apparent at the
peak of LN expansion and corresponded with a reduced fre-
quency of CD44hiCD27lo effector cells (Figure 3D) and few
transferred memory cells infiltrating the CNS (Figure 3E). Trans-
fer of cells into IL-23R/ naive recipient mice, in which endog-
enous T cells do not form effector Th17 responses (McGeachy
et al., 2009), resulted in a disease course similar to transfer into
wild-type (WT) hosts (Figure S4A), and this was effectively
blocked by anti-IL-23R treatment. Furthermore, memory cells
induced EAE in RAG-deficient animals that lack endogenous
T cells, and these effects were also dependent on IL-23 (Fig-
ure S4B), confirming that these transferred Th17 memory cells
alone are sufficient to initiate EAE when activated in the pres-
ence of IL-23. Given that MOG is a self-antigen, we also tested
whether similar IL-23-dependent Th17 memory responses
could be induced using the putative nonself immunogenicell Reports 3, 1378–1388, May 30, 2013 ª2013 The Authors 1379
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Figure 1. Autoimmune Memory Cells Transfer Severe EAE
Donor C57Bl/6micewere immunizedwithMOG(35-55). dLNs and spleens were harvested 30 days later and CD4+ cells (memory cells) were transferred into naive
CD45.1+ congenic recipients. The recipients were rested for 2–3 weeks (except for the recipients shown in B, which were rested for 9 weeks posttransfer) and
then immunized to induce EAE.
(A) Mean clinical scores of memory transfer recipients that were immunized or not immunized, and immunized controls that did not receive any memory cells.
(B) Mean clinical scores of memory transfer recipients that were rested for 9 weeks before immunization.
(C) Time course of transferred memory cells analyzed by flow cytometry for CD45.2+ surface expression and shown as a percentage of the CD4+ cell population;
representative dot plots and pooled data are shown. Day 0 is equivalent to unimmunized recipient of memory cell transfer.
(legend continued on next page)
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peptide OVA(323-339) as the immunizing antigen. Indeed, we
observed similar expansion and cytokine production by trans-
ferred T cells in this OVA-driven recall assay (Figure S5).
Anti-IL-23R Inhibits the Generation of Large Numbers of
Cytokine-Producing Effector Cells
We previously reported that IL-23R blockade during the primary
response both reduced the percentage of IL-17+ cells in the pe-
riphery and impaired the resulting effector response (McGeachy
et al., 2009). In contrast, in the present study, IL-23R blockade
did not reduce the percentage of IL-17 producers during the
memory response (Figure 4A), and instead drastically reduced
the absolute number of IL-17+ cells (Figure 4B). The IL-
17+IFNg+ and IL-17IFNg+ populations were also reduced in
both percentage and number at day 7 in the LNs (Figures 4C
and 4D). It was recently reported that IL-23 is required for gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF) pro-
duction by Th17 cells in EAE (Codarri et al., 2011; El-Behi
et al., 2011). In our memory population, GM-CSF producers
were not significantly reduced as a percentage of memory cells
(Figure 4E). However, similarly to IL-17, there was a significant
decrease in the absolute numbers of GM-CSF+ cells when
anti-IL-23R was administered (Figure 4F). In the target tissue
(CNS), the percentage of memory cells producing IL-17 was
again not different, but IL-17+IFNg+ and IL-17IFNg+ cells were
reduced with anti-IL-23R (Figure 4G). Corresponding with
reduced IFNg, T-bet expression was also reduced when IL-23
signals were blocked during the secondary response (Figure 4I).
Similar reductions in T-bet expression by primary Th17 cells acti-
vated in IL-23 knockout mice were recently reported (Hirota
et al., 2011). Therefore, induction of T-bet and IFNg appear to
be part of the Th17 program initiated by IL-23 in vivo. Interest-
ingly, Yeh et al. (2011) reported that IL-12 is not required for
T-bet expression in EAE.
It remains unclear what the functions of T-bet and IFNg are
in Th17 cells. Although T-bet is thought to be required for
autoimmune inflammation (Lazarevic and Glimcher, 2011),
IFNg is not, at least in commonly used models. It was recently
proposed that T-bet inhibits RORgt in Th17 cells through bind-
ing to the cofactor RUNX1 (Lazarevic et al., 2011), and T-bet-
deficient animals do have increased numbers of IL-17+ cells
despite their resistance to autoimmunity. However, it is clear
that in human chronically inflamed tissues, such as the inflamed
colon in Crohn’s disease or brain lesions in multiple sclerosis,
these double-producing cells are found in high numbers (Kebir
et al., 2009; Kleinschek et al., 2009). In our study we also
observed a high frequency of double-positive cells expressing
RORgt and T-bet as well as IL-17 and IFNg, and this coex-
pression was dependent on IL-23, suggesting a proinflamma-(D) Surface expression of CD44 and CD27 analyzed by flow cytometry at the ind
(E) Ex vivo intracellular cytokine analysis of IL-17 and IFNg in memory cells from
(F) Memory cells in blood, analyzed by expression of CD45.2 at the indicated tim
(G) Memory cells in the CNS in an unimmunized transfer recipient (naive) and on
(H) Ex vivo intracellular cytokine analysis of IL-17 and IFNg in CD4+ cells, gatin
populations taken from the CNS on day 12. Data shown are representative of at l
graphs show mean and SD.
See also Figure S1.
Ctory role for these cells. Furthermore, a high proportion of
RORgt+T-bet+ cells produced IL-17 but not IFNg in vivo. There-
fore, the relationship between T-bet and Th17 cells warrants
further investigation.
Anti-IL-23R Reduces the Number of Proliferating
Memory Cells
The findings so far suggest that IL-23 is required for the memory
Th17 response, but not necessarily for production of IL-17
or other Th17-associated factors. Rather, the biggest defect
appeared to be in the number of cells generated, suggesting a
proliferation defect. Analysis of Ki67 expression in the memory
cells confirmed that proliferation was indeed being affected by
IL-23R blockade (Figure 5A).
Since we previously observed that IL-23 drives expansion of
effector Th17 cells in the primary response (McGeachy et al.,
2009), we turned to a system that allowedmore in-depth analysis
of the effects of IL-23 on proliferation. Using adoptive transfer of
OTII cells, which have a transgenic T cell receptor specific for
OVA(323-339), we were able to generate activated cells (all
CD44hi) by immunizing recipients as previously described
(McGeachy et al., 2009). We then sorted the OTII cells based
on IL-17 expression for messenger RNA (mRNA) analysis. By
comparing IL-17+ and IL-17 cells derived from the same anti-
gen-specific activated T cell population, we were able to ask
which genes were differentially regulated. Il17a was increased
in IL-17+ cells, confirming sort purity (Figure 5B). Ki67 was also
upregulated in IL-17+ cells and reduced in IL-23R-deficient cells,
as expected (Figure 5C). Furthermore, Il23ra expression corre-
lated with Il17 expression, being increased on IL-17+ cells
compared with IL-17 cells, further confirming that IL-23
signaling drives proliferation in Th17 cells (Figure 5D).
We then investigated the expression of genes that are involved
in cell cycle. Many of these genes were indeed upregulated in
IL-17+ cells compared with IL-17 cells (Figure 5E). These
included genes for transcription factors that regulate cell-cycle
progression (E2F, Tfdp, Myb, cdc, and cyclin families), genes
for enzymes required for DNA replication (polymerases, ligases,
and primases) as well as DNA repair proteins of the Brca andChk
families, and genes involved in chromosome assembly and
segregation during division (Cenp, Kif, Haus, and Ncap families).
The expression pattern of Il23ra/ IL-17+ cells showed that
there was at least a 2-fold downregulation in almost all cell-cycle
genes that were associated with WT IL-17+ cells (Figure 5F). Not
all genes were downregulated in the Il23ra/ IL-17+ cells: Il17a,
Rorc, and Il17f were unchanged, confirming previous reports
that upregulation of Rorc does not require IL-23.
To confirm that the same defect is responsible for the
reduced proliferation in memory Th17 cells, IL-17+ cells wereicated time points.
dLNs after 4 hr of stimulation in vitro with PMA and ionomycin.
e points.
day 12 postimmunization (EAE).
g on CD45.1+ host endogenous cells and CD45.2+ transferred memory cell
east three independent experiments with at least four mice per group; bars on
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Figure 2. Th17 Memory Cells Are Generated
from Primary IL-17+ and RORgt+ Precursors
(A–E) Donor IL-17-GFP reporter mice were immunized
with MOG(35-55) in CFA, and dLNs and spleens were
harvested 8 days (A–C) or 18 days (D) later.
CD4+CD44+GFP+ or GFP cells were FACS sorted and
transferred into naive CD45.1+ congenic recipients.
After resting for 3 weeks, recipients were immunized to
induce EAE.
(A) Mean clinical scores of immunized recipients of
IL-17-GFP+ or IL-17-GFP.
(B) Percentage and number of transferred IL-17-GFP+
and IL-17-GFP cells in the CNS on day 11 post-
immunization.
(C and D) Intracellular cytokine analysis, following
stimulation with PMA and ionomycin, of IL-17 and IFNg
gating on transferred CD45.2+ cells in recipient dLNs
on day 5 and day 11 postimmunization, and from the
CNS on day 11.
(E) Comparison of cytokine expression in
CD4+CD45.2+ day 8 and day 18 transfer cells taken
from the CNS of immunized recipients on day 11.
(F–I) Donor RORgtGFP reporter mice were immunized
with MOG(35-55), and dLNs and spleens were har-
vested 18 days later. CD4+CD44+GFP+ or GFP cells
were FACS sorted and transferred into naive CD45.1+
congenic recipients. After resting for 3 weeks, re-
cipients were immunized to induce EAE.
(F) Intracellular cytokine analysis of transferred cells in
LNs of immunized recipients of RORgtGFP+ cells,
gated on CD4+CD54.2+ cells.
(G) Intracellular cytokine analysis, gating on
CD4+CD45.2+ RORgt+ (GFP+) and RORgt (GFP)
cells in LNs of immunized recipients of RORgtGFP+
cells.
(H) T-bet and RORgt (analyzed by GFP) expression in
CD4+CD45.2+ cells from LNs of immunized recipients
of RORgtGFP+ transfers.
(I) Expression of IL-17 and T-bet following PMA and
ionomycin stimulation, gating on CD4+CD45.2+
RORgt+ (GFP+) and RORgt (GFP) cells in LNs
on day 13 postimmunization from recipients of
RORgtGFP+ cells. Data shown are representative of at
least two independent experiments with three to four
mice per group; bars on graphs show mean and SD.
See also Figure S2.sorted from memory populations activated in vivo in the pres-
ence of anti-IL-23R or an isotype control antibody. Again,
gene expression for Il-17a was not different between the two
populations, confirming the sort integrity (Figure 5G). Il21 and
Il1r1 expression were not significantly altered by IL-23R
blockade (Figures 5H and 5I), suggesting that IL-23 is not
absolutely required for production of IL-21 or responsiveness1382 Cell Reports 3, 1378–1388, May 30, 2013 ª2013 The Authorsto IL-1R1, two factors known to be required
for Th17 development in vivo (Korn et al.,
2007; Nurieva et al., 2007; Sutton et al.,
2006). A similar pattern of cell-cycle-associ-
ated gene downregulation was observed in
memory IL-17+ cells that had been activated
in vivo in the absence of IL-23 signals
(Figure 5J).IL-23 could regulate these proliferation-associated genes
directly or indirectly by activating ‘‘intermediary’’ transcription
factors. We therefore asked which of the genes we had identified
were upregulated within a short time frame and therefore likely
to be directly regulated by IL-23. IL-17+ cells were isolated
from LNs on day 4 postimmunization with MOG(35-55)-CFA
and stimulated in vitro with IL-23 only, for 2 hr. Tfdp1, Tfdp2,
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Figure 3. IL-23 Is Required for Secondary Activation of the Th17 Memory Response
C57Bl/6 mice were immunized with MOG(35-55), dLN and spleen were harvested 30 days later, and CD4+ cells were transferred into naive CD45.1+ congenic
recipients. After resting for 2–3weeks, recipients were immunized to induce EAE and either anti-IL-23R or isotype control antibodywas administered on the day of
EAE induction.
(A) Mean EAE scores of memory transfer recipients after immunization.
(B) EAE scores of mice transferred as in (A) and immunized with MOG(35-55) emulsified in IFA.
(C) Time course of the percentage and number of transferred memory cells in LNs, analyzed by flow cytometry for CD45.2+ surface expression.
(D) Percentage of transferred memory cells that were effector cells (CD44hiCD27lo), analyzed by flow cytometry from dLNs on day 7.
(E) Percentage and number of transferred memory cells in CNS on day 12 postimmunization. Data shown are representative of at least three independent
experiments with four mice per group (in some plots, data are pooled from multiple experiments); bars on graphs show mean and SD.
See also Figures S1, S3, S4, and S5.
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Figure 4. Anti-IL-23R Inhibits the Generation of Large Numbers of Cytokine-Producing Effectors
Memory cells were transferred and recipients immunized as in Figure 3.
(A and B) Time course of IL-17+ memory cells (transferred and activated as in Figure 3) from LNs, analyzed following 4 hr stimulation ex vivo with PMA and
ionomycin at the indicated time points.
(C and D) Time course of percentage and number of IFNg+ and IL-17+IFNg+ cells cells in LN.
(E and F) Time course of percentage and number of GM-CSF+ transferred memory cells from LN.
(G and H) Percentage and number of IL-17+, IFNg+, and IL-17+IFNg+ cells in CNS on day 12, analyzed by intracellular cytokine staining.
(I) Percentage of T-bet+ transferred memory cells in LNs on day 13. Data shown are representative of at least three independent experiments with at least four
mice per group (except for E and F, which show two independent experiments). Bars on graphs show mean and SD.
See also Figure S1.and E2f2 were rapidly upregulated in response to IL-23 (Figures
5K–5M). The function of these genes remains to be tested, but
these data strongly suggest that many of the genes that require1384 Cell Reports 3, 1378–1388, May 30, 2013 ª2013 The AuthorsIL-23R expression are activated indirectly, and that IL-23 acti-
vates key transcription factors in addition to STAT3 to mediate
its downstream proliferation effects.
When we compare the primary and secondary requirements
for activation of Th17 cells, it is clear that IL-23 is important for
both stages. Blockade of IL-23 resulted in fewer effector cells
migrating to the blood and tissues, as well as fewer IFNg+ cells,
and this was associated with reduced proliferation in both the
primary and recall responses, although the effects on prolifera-
tion were most pronounced in the memory response. Although
we did not find regulation of the antiapoptotic factor Bcl2, the
observed reduction of multiple proteins required for DNA repair
pathways, such as BRCA1 and BRCA2, would increase the sus-
ceptibility of dividing cells to apoptosis, further reducing the
number of cycling cells when IL-23 is absent. In this regard, it
is interesting that IL-1, another cytokine that is critical for Th17
development in both mice and humans, has been shown to pro-
mote proliferation of Th17 cells through activation of the mTOR
pathway (Gulen et al., 2010). IL-1 is required early in Th17 devel-
opment (Chung et al., 2009), whereas the effects of IL-23
become more apparent later (McGeachy et al., 2009). Whether
IL-1 and IL-23 cooperate directly to promote proliferation or
act at different stages of development remains unclear.
Kryczek et al. (2011) recently characterizedmemory Th17 cells
found in three types of chronic inflammation of the digestive sys-
tem in human patients: chronic graft-versus-host disease, ulcer-
ative colitis, and colon cancer. They found that Th17 cells were a
more stable population than was previously reported, in agree-
ment with our finding that the IL-17-producing Th17 phenotype
was recapitulated in the memory response. Supporting the role
of human Th17 memory cells in chronic disease, Kryczek et al.
also reported that these cells appear to be a robust population
that is resistant to apoptosis and is associated with high expres-
sion of the antiapoptotic genes BCLXL and Bcl2. In their experi-
ments, viability was not influenced by IL-23; rather, HIF1was pro-
posed to regulate Bcl2. Importantly, human Th17 memory cells
were also found to have greater proliferative capacity than other
subsets. In our system, we also found that autoimmune IL-17+
cells had increased proliferation compared with their IL-17
counterparts, and further demonstrated that multiple cell-cycle-
associated genes were strongly regulated by IL-23. Therefore,
our resultscorrespondwithandextendfindings that areemerging
from studies of human samples, and highlight the potential ther-
apeutic utility of neutralizing IL-23 in chronic inflammatory and
autoimmune diseases associated with memory Th17 cells.
EXPERIMENTAL PROCEDURES
Mice
Il23ra–/–OTII+CD45.1+ mice (Chan et al., 2006) were generated at Merck (Palo
Alto, CA, USA). C57Bl/6 and CD45.1+ mice purchased from The Jackson Lab-
oratory (Bar Harbor, ME, USA). IL-17-GFP reporter mice were purchased from
Biocytogen (Worcester, MA, USA). RORgt-GFP reporter mice were a kind gift
from Dr. Gerard Eberl (Institut Pasteur, Paris). The animals were housed in an
AAALAC-approved facility and procedures were approved by the Merck Palo
Alto IACUC committee.
Memory Cell Transfers
Donor C57Bl/6 mice (or IL-23R-GFP reporter mice where indicated) were
immunized with 100 mg MOG(35-55) in 200 ml CFA containing 100 mg heat-
killed M. tuberculosis H37Ra (Difco, Detroit, MI, USA) in four sites on the
back. For IL-23R neutralization, a single dose of 800 mg anti-IL-23R (21A4)
or isotype control was delivered intraperitoneally at the indicated time pointsCto either donor or recipient mice. Draining LNs (dLNs) and spleens were har-
vested 30 days postimmunization, and CD4+ cells were isolated by magnetic
separation using CD4 microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Seven million CD4+ cells were transferred intravenously into naive
CD45.1 congenic recipients. For IL-17-GFP and RORgt-GFP transfers, donors
were immunized as before, and dLNs were harvested on either day 8 or day 18
as indicated. Cells were labeled with fluorescent antibodies for CD4/CD44 and
were sorted into CD44hiGFP+ and CD44hiGFP populations. A total of 200,000
cells were transferred into naive congenic recipients.
EAE Induction
EAE was induced 2–3 weeks following transfer of memory cells. Recipient
mice or untransferred controls were immunized with 100 mg MOG(35-55) in
200 ml CFA containing 100 mg heat-killed M. tuberculosis H37Ra in four sites
on the back and received 100 ng pertussis toxin (List Biological Laboratories,
Campbell, CA, USA) intraperitoneally on days 0 and 2. EAE was assessed
according to the following clinical grades: 1 = flaccid tail; 2 = impaired righting
reflex and hindlimb weakness; 3 = partial hindlimb paralysis; 4 = complete
hindlimb paralysis; 5 = hindlimb paralysis with partial forelimb paralysis;
6 = moribund/dead. Mouse anti-mouse IL-23R monoclonal antibody (21A4)
and isotype control (27F11, mouse IgG1) were generated at Merck, and
700 mg/mouse was administered intraperitoneally.
Flow Cytometry
LNs, blood, and CNSmononuclear cells were isolated as previously described
(Cua et al., 2003; Langrish et al., 2005) frommice with EAE and single-cell sus-
pensions were obtained. For cytokine analysis, cells were cultured in complete
medium (RPMI media containing 10% fetal calf serum supplemented with
Pen-Strep, L-Glutamine, HEPES, sodium pyruvate, and 2-ME) with 50 ng/ml
phorbol myristate acetate (PMA) and 500 ng/ml ionomycin (both Sigma-
Aldrich, St. Louis, MO, USA) in the presence of Golgiplug (BD Biosciences,
San Jose, CA, USA) for 3–4 hr, followed by fluorescence-activated cell sorting
(FACS) staining and analysis. The following FACS antibodies were purchased
from BD Biosciences: CD4 (RM4-5), CD45.1 (A20), CD45.2(104) CD44 (IM7),
CD27 (LG.3A10), CCR6 (140706), Ki67 (B56), IFN-g (XMG1.2), IL-17 (TC11-
18H10), and IL-2 (JES6-5H4). Ki67 and intracellular cytokine staining were per-
formed using the Cytofix/Cytoperm kit (BD) according to the manufacturer’s
instructions. T-bet (eBio4B10) and GM-CSF (MP1-22E9) were purchased
from eBioscience.
OTII Cell Transfer and Sorting
Recipient mice (CD45.2+) received 105 CD45.1+ Il23ra/, Il23ra+/+ OTII CD4+
T cells intravenously 1 day before immunization with 100 mg OVA(323-339) in
CFA subcutaneously in the flank. On day 7 postimmunization, dLNs were har-
vested and cells were stimulated with PMA and ionomycin for 2.5 hr. Cells
were stained for CD4, CD45.1, and intracellular IL-17, with the addition of ribo-
nucleoside vanadyl complexes (Sigma) before they were sorted on a FACSAria
cell sorter based on IL-17 expression. The sorted cells were snap-frozen
at 80C and then processed for RNA analysis.
Real-Time PCR
Total RNA was isolated using the High Pure FFPE RNA Micro Kit (Roche,
Mannheim, Germany) per the manufacturer’s protocol. DNase-treated total
RNA was amplified using the NuGen WT-Ovation Pico RNA Amplification
System (NuGen Technologies, San Carlos, CA, USA) per the manufac-
turer’s instructions. Primers were designed using Primer Express (Applied
Biosystems/Life Technologies, Foster City, CA, USA) or obtained commer-
cially from Applied Biosystems. Real-time quantitative PCR on 10 ng of
amplified complementary DNA (cDNA) from each sample was performed on
the Fluidigm BioMark system (Fluidigm, Foster City, CA, USA). Ubiquitin levels
were measured in a separate reaction and used to normalize the data by the
d-d Ct method.
Statistics
When appropriate, a one-way ANOVA (for multiple groups) or Student’s t test
was performed for experiments with parametric values (such as FACS per-
centage). The Mann-Whitney test or Kruskal-Wallis test was performed forell Reports 3, 1378–1388, May 30, 2013 ª2013 The Authors 1385
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Figure 5. IL-23 Regulates the Cell Cycle to Expand Both Primary and Memory Th17 Cells
(A) Memory cells were transferred and recipients immunized as in Figure 3. Expression of Ki67 and IL-17 was analyzed in LNs by flow cytometry at the indicated
time points.
(B–F) C57Bl/6 mice received either WT or Il23ra/OTII+CD45.1+CD4+ T cells 1 day before immunization with OVA(323-339) in CFA. On day 7 postimmunization,
OTII cells from dLNs were sorted based on IL-17 expression, and gene-expression analysis was performed. The relative expression of (B) Il17a, (C) Ki67, and
(D) Il23ra is shown.
(E) Heatmap of values for the indicated genes expressed as fold change between IL-17+ and IL-17 WT OTII cells.
(F) Heatmap of values for the indicated genes, expressed as fold change between WT IL-17+ and Il-23ra/ IL-17+ OTII cells. An arbitrary maximum threshold
range of 10 to +10 was selected, with any values falling outside of that range designated as the maximum value.
(legend continued on next page)
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EAE experiments, with scores for each day analyzed separately; p values are
shown as *p < 0.05, **p < 0.01, and ***p < 0.001 where statistical significance
was found, and all data are represented as means ± SD.SUPPLEMENTAL INFORMATION
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